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In the present study, we hypothesized that HIV-1–in-
duced occult HIV-associated nephropathy (HIVAN)
would become apparent in the presence of adverse host
factors. To test our hypothesis, Vpr mice (which display
doxycycline-dependent Vpr expression in podocytes)
with two, three, and four copies of the angiotensinogen
(Agt) gene (Vpr-Agt-2, Vpr-Agt-3, and Vpr-Agt-4) were
administered doxycycline for 3 weeks (to develop clin-
ically occult HIVAN) followed by doxycycline-free water
during the next 3 weeks. Subsequently, renal biomark-
ers were measured, and kidneys were harvested for
renal histology. Vpr-Agt-2 developed neither protein-
uria nor elevated blood pressure, and displayed mini-
mal glomerular and tubular lesions only, without any
microcyst formation. Vpr-Agt-3 showed mild glomerular
and tubular lesions and microcyst formation, whereas
Vpr-Agt-4 showed moderate proteinuria, hypertension,
glomerular sclerosis, tubular dilation, microcysts, and ex-
pression of epithelial mesenchymal transition markers.
Vpr-Agt-4 not only displayed enhanced renal tissue ex-
pression of Agt, renin, and angiotensin-converting en-
zyme, but also had higher renal tissue concentrations of
angiotensin II. Moreover, renal cells in Vpr-Agt-4 showed
enhanced expression of transforming growth factor-,
connective tissue growth factor, and vascular endothelial
growth factor. These findings indicate that adverse host
factors, such as the activation of the renin-angiotensin
system, promote the progression of occult HIVAN to ap-
parent HIVAN. (Am J Pathol 2011, 179:1681–1692; DOI:
10.1016/j.ajpath.2011.06.013)
HIV-associated nephropathy (HIVAN) is an important
complication of HIV-1 infection in patients of African-American background.1–3 It is characterized by focal glo-
merulosclerosis and microcystic dilation of tubules.4 Re-
nal biopsy data suggested that HIV-1 infection of
glomerular and tubular cells contributed to HIVAN phe-
notype.5 Since the advent of highly active anti-retroviral
therapy (HAART), many patients with HIV-1 infection are
able to achieve undetectable viral load and, even those
that do not, live a normal life span; on that account, we
hypothesized that patients with HIV-1 infection might ac-
quire renal cell HIV-1 expression during the period of
higher viral load, and these patients might develop ap-
parent kidney lesions in the later time period, during the
presence of adverse host factors, such as the activation
of the renin-angiotensin system (RAS).6–8 In addition,
patients with HIV-1 infection are increasingly prone to
develop hypertension, diabetes, and obesity as they
age.9–12 Because diabetes and hypertension are the
commonest causes of glomerulosclerosis in patients of
African-American background, these patients would be
prone to display glomerulosclerosis if they developed
HIV infection, too.13–15 In the absence of kidney biopsy,
at times it may be difficult to differentiate clinically the
exact etiology of proteinuria in these patients.
Podocyte injury has been considered to be a key event
in the development of both classical and collapsing vari-
ant of focal glomerular sclerosis.16 Podocyte HIV-1 infec-
tion has been reported in patients with HIVAN.17 Several
investigators have demonstrated that podocyte expres-
sion of an individual protein is sufficient to initiate the
development of focal glomerulosclerosis.18 In a scenario
where HIV-1 had invoked podocyte HIV-1 protein expres-
sion (before the administration of HAART), podocytes will
continue to express HIV-1 proteins (being a terminally
differentiated cell) despite undetectable viral load (as a
consequence of HAART), because current antiviral ther-
apy inhibits viral replication only, but does not attenuate
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currence of HIVAN requires presence of specific genetic,
environmental, and host factors, mere podocyte expres-
sion of HIV-1 protein (environmental factor) and genetic
background (African ancestry) may not be sufficient to
invoke the HIVAN phenotype.17 We hypothesized that
manifestation of HIVAN phenotype, in this scenario, will
also requires specific host factors, such as activation of
the RAS, along with genetic and environmental factors.19
To test our hypothesis, we have used the Vpr mouse
model of HIVAN (having the murine strain FVB/N as its
genetic background), in which podocyte expression of
Vpr (environmental factor) is evaluated for the progres-
sion of occult HIVAN to apparent HIVAN phenotype in the
presence or absence of the specific host factors. To
promote endogenous activation of the RAS in Vpr mice,
we have used Vpr mice with variable (two, three, and
four) copies of angiotensinogen. Since epithelial mes-
enchymal transition (EMT) has been demonstrated to
play an important role in the progression of kidney
fibrosis, we studied renal tissue molecular markers of
EMT in Vpr mice.
Materials and Methods
Vpr Mice
Breeding pairs of FVB/N were obtained from Jackson
Laboratories (Bar Harbor, ME). Breeding pairs to de-
velop Vpr colonies were kindly provided by Prof. Jef-
fery B. Kopp, National Institutes of Health, Bethesda,
MD. We have generated Vpr transgenic animals by
crossing podocin/rtTA (constitutively expresses the
rtTA, which is a fusion protein comprised of the TetR
repressor and the VP16 transactivation domain ex-
pressed under control of the podocin promoter) mice
with tetop/Vpr mice (TRE-regulated Vpr gene). These
animals were fed doxycycline in their drinking water to
induce the expression of the podocyte-specific Vpr
gene. These animals develop apparent HIVAN pheno-
type only after 6 weeks of doxycycline administration.
We have used two descriptive terms to describe the
presence (apparent) or absence (occult) of proteinuria
and high blood pressure to identify HIVAN, with the
presumption that if Vpr mice developed any renal dis-
ease, it was going to be HIVAN. We observed that after
3 weeks of doxycycline administration, Vpr mice de-
veloped either no or minimal renal lesions with absence
of abnormal proteinuria and blood pressure levels. We
called these renal lesions occult HIVAN; on the other
hand, when Vpr mice developed abnormal proteinuria
and blood pressure, we called it apparent HIVAN. The
Ethics Review Committee for Animal Experimentation
of the Feinstein Institute for Medical Research ap-
proved the experimental protocol.
Experimental Approach
Unlike the pharmacological modulation of angiotensin II
(Ang II) carried out in previous studies, we have genetically
modulated the levels of Ang II, which helps to obviate theadditional, unwanted effects of the pharmacological agents
other than their effect on the RAS. In the present study, we
have used a genetically engineered mouse model (Vpr
mice) to study the role of the RAS activation in the progres-
sion of occult HIVAN to apparent HIVAN. To develop ap-
parent HIVAN phenotype, Vpr mice required 6 weeks of
doxycycline treatment. Since Vpr mice developed occult
HIVAN (only minimal renal lesions, no proteinuria and blood
pressure) only after 3 weeks of doxycycline therapy, we
have stopped doxycycline therapy after 3 weeks in all of the
groups (protocol C). Blood pressure remained the same.
Agt Transgenic Mice
We obtained Agtdup/Agtdup mice from the Jackson Labo-
ratories. Since these mice were not on an FVB/N back-
ground, we have bred them with FVB/N for eight gener-
ations. Homozygous Agt mice (Agtdup/Agtdup) are viable
and fertile. They show blood pressure levels 16 mm Hg
higher than their normal wild-type siblings (Agt/Agt).
Heterozygous mice (Agt/Agtdup) show blood pressure
levels 8 mm Hg higher than their normal wild-type sib-
lings. This transgenic mouse model demonstrates the
causality between genotype at the angiotensinogen lo-
cus and blood pressures. Blood pressures of one-copy
(Agttm1Unc/) through four-copy (Agtdup/Agtdup) animals
show significant and almost linear increases of approxi-
mately 8 mm Hg per gene copy despite their normal
compensatory mechanisms being intact.20
To generate Vpr mice with variable Agt copies, Vpr
mice were bred with Agtdup/Agtdup mice (Figure 1). Geno-
typing assays to distinguish between the different allele
of the Agt gene (Agt and Agtdup) have been established
at the Jackson Laboratory. The tail DNA of the progeny
was analyzed by PCR. The Agtdup allele produced
a 190-bp fragment when amplified with the D8Mit56
marker, whereas Agt gave a 160-bp fragment. The se-
quences of the two primers that were used are as follows:
5=-ACACTCAGAGACCATGAGTACACC-3= SSLP primer
D11Mit 258 and 5=-GAGTTCACTACCCACAAGTCTCC-3=
SSLP primer D11Mit258. The inheritance of the other
transgenes (tetop/vpr and podocin/rtta) was determined
by PCR, using the following primers: forward 5=-CGC-
CTGGAGACGCCATCC-3= and reverse 5=-CCACACCTC-
CCCCTGAAC-3=.
Figure 1. Generation of Vpr animals that have two (Agt/Agt), three
(Agtdup/Agt), or four (Agtdup/Agtdup) functional copies of the angiotensino-
gen (Agt) gene at its normal chromosomal location. Since Tetop/Vpr and
Podocin/rTTA mice were on the FVBN background, we have used the Agtdup
FVBN congenic strains. *Animals were generated such that the animals used
for the breeding were homozygous for the Tetop/Vpr or Podocin/rTTA trans-
gene. **Animals were generated such that the animals used for the breeding
were hemizygous for the Tetop/Vpr or Podocin/rTTA transgene.
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Protocol A
To determine the development of clinically apparent
HIVAN phenotype in Vpr mice, 6-week-old age- and sex-
matched Vpr-Agt-2 mice, were fed either doxycycline
(Doxy-Vpr) or normal saline (C-Vpr) in their drinking water
for 6 weeks (n  6 for each group). At the end of the
experimental period, renal disease biomarkers were col-
lected, and kidneys were harvested for renal histology.
Protocol B
To determine the effect of the RAS on the progression
of HIVAN in Vpr mice, 6-week-old, age- and sex-matched
Vpr-Agt-2, Vpr-Agt-3, and Vpr Agt-4 mice (n  6) were
fed drinking water containing doxycycline for 6 weeks. At
the end of the experimental period, biomarkers were col-
lected, and kidneys were harvested for renal histology.
Protocol C
To evaluate the effect of the activation of the RAS on
clinically occult HIVAN, 6-week-old, age- and sex-
matched Vpr-Agt-2, Vpr-Agt-3, and Vpr Agt-4 mice (n 
6) were fed drinking water containing doxycycline for 3
weeks (to develop occult HIVAN) followed by drinking
water without doxycycline for 3 weeks. At the end of
experimental periods, renal biomarkers were collected,
and kidneys were harvested for renal histology.
Renal Disease Biomarkers
Five primary biomarkers related to renal disease were
included: blood pressure, renal histology, proteinuria (uri-
nary protein/creatinine ratio mg/g creatinine), and bio-
chemical parameters (blood urea nitrogen and serum
albumin). Blood pressure (systolic and diastolic) was
measured by CODA system (Kent Scientific, Torrington,
CT) at 2-week interval. Proteinuria was measured by au-
tomated analyzer, which quantified the levels as low as
1.0 g/mL; blood was obtained at the end of the exper-
imental protocol by cardiac puncture (under anesthesia)
at the time of sacrifice.Renal Histology
Renal cortical sections were stained with hematoxylin and
eosin, and PAS. Renal histology was scored for both tubular
and glomerular injury. Renal cortical sections were coded
and examined under light microscopy. Twenty random
fields (20)/mouse were examined to score percentage of
the involved glomeruli and tubules. Glomerular lesions were
classified as focal segmental glomerulosclerosis, global
glomerulosclerosis, and collapsing glomerulosclerosis. A
semiquantitative scale—0  no tubular dilation, 1  min-
imal tubular dilation, 2  mild tubular dilation, and 3 
moderate tubular dilation—were used for scoring. In
addition, total number of microcysts was counted and per-
centage was calculated.
Immunohistochemical Staining
The immunohistochemistry protocol used in the present
study has been described previously.21 Briefly, the sections
were de-paraffinized, and antigen retrieval was accom-
plished by microwave heating for 10 minutes at the maxi-
mum output in 10 mmol/L citrate buffer (pH 6.0). The en-
dogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide in methanol for 30 minutes at room tem-
perature. Sections were washed in phosphate buffered sa-
line (PBS) thrice and incubated in blocking serum solution
according to the primary antibody for 1 hour at room tem-
perature. The primary antibody was applied in different di-
lutions: transforming growth factor- (TGF-) (rabbit poly-
clonal, dilution 1:200; Santa Cruz Biotechnology, Santa
Cruz, CA), connective tissue growth factor (CTGF) (goat
polyclonal, dilution, 1:200; Santa Cruz Biotechnology), an-
giotensinogen (rabbit monoclonal, 1:600; Epitomics, Burlin-
game, CA), renin (rabbit polyclonal, dilution 1: 400; Santa
Cruz Biotechnology), and vascular endothelial growth factor
(VEGF) (mouse monoclonal, 1:1000; Santa Cruz Biotech-
nology) and then incubated overnight at 4°C in a humidify-
ing chamber. Each of the sections were washed thrice with
PBS and incubated in the appropriate secondary antibody
at 1:250 dilutions at room temperature for 1 hour. After
washing with PBS three times, sections were incubated in
ABC reagent (Vector Laboratories, Burlingame, CA) for 30
minutes. Sections were washed thrice in PBS and placed in
VECTOR Nova RED substrate kit SK-4800 (Vector Labora-
Figure 2. Doxy-Vpr manifest the HIVAN phe-
notype. Renal cortical sections from the protocol
A were stained with PAS and graded for severity
of renal lesions. Representative microphoto-
graphs of renal cortical sections Doxy-Vpr and
C-Vpr are shown. C-Vpr did not reveal any glo-
merular or tubular abnormalities; whereas,
Doxy-Vpr showed both segmental glomerular
lesions and microcyst formation. Segmental le-
sions are shown by black arrows; whereas mi-
crocyst formation is indicated by a black
arrowhead.
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The sections were then dehydrated and mounted with
a xylene-free mounting media (Permount; Fisher Sci-
entific, Fair Lawn, NJ). In all of the batches of immu-
noassaying, appropriate positive and negative controls
were used. All of the immune-stained slides were
coded and blindly studied by two pathologists by a
semiquantitative grading score.
Reverse-Transcription PCR Analysis
Control and experimental renal tissues were used to
quantify mRNA expression of molecules pertaining to the
RAS and EMT. RNA was extracted using TRIZOL (Invit-
rogen, Carlsbad, CA). For cDNA synthesis, 2 g of the
total RNA was preincubated with 2 nmol of random hex-
amer (Invitrogen) at 65°C for 5 minutes. Subsequently, 8
L of the reverse transcriptase reaction mixture contain-
ing Cloned AMV reverse transcriptase, 0.5 mmol each of
the mixed nucleotides, 0.01 mol dithiothreitol, and 1000
U/mL RNAsin (Invitrogen) was incubated at 42°C for 50
minutes. For a negative control, a reaction mixture without
RNA or reverse transcriptase was used. Samples were
subsequently incubated at 85°C for 5 minutes to inacti-
vate the reverse transcriptase. Quantitative PCR was car-
ried out in an ABI Prism 7900HT sequence detection
Figure 3. Renal tissue expression of EMT markers in Doxy-Vpr. Total RNA
was extracted from renal tissues of Doxy-Vpr and C-Vpr (n  3). RNA was
probed for PCNA, -SMA, FSP1, SNAIL, ZEB2, and ZEB1. *P 0.01 compared
with respective C-Vpr; **P  0.001 compared with respective C-Vpr. Error
bars indicate SD.
Figure 4. Vpr with higher Agt copies developed advanced renal lesions. R
(protocol B). Vpr-Agt-4 showed enhanced number of glomerular sclerotic lesions an
arrows; whereas microcyst formation is indicated by arrowheads.system (Applied Biosystems, Life Technologies Corpora-
tion. Carlsbad, CA using the primer sequences as shown
below: Agt (forward, 5=-ACACTCAGAGACCATGAGTA-
CACC-3=; reverse 5=-GAGTTCACTACCCACAAGTCTCC-
3=); -smooth muscle actin (-SMA) (forward 5=-CT-
GACAGAGGCACCACTGAA-3=; reverse 5=-CATCTCCA-
GAGTCCAGCACA-3=); fibroblast-specific protein 1
(FSP1) (forward 5=-GATGAGCAACTTGGACAGCA-3=; re-
verse 5=-ATGTGCGAAGAAGCCAGAGT-3=); proliferating
cell nuclear antigen (PCNA) (forward 5=-GGGTTGG-
TAGTTGTCGCTGT-3=; reverse 5=-AGCACCTTCTTCAG-
GATGGA-3=); SNAIL (forward 5=-ATTCTCCTGCTC-
CCACTGC-3=; reverse 5=-GACTCTTGGTGCTTGTGGAG-
3=); zinc finger E-box-binding homeobox 1 (ZEB1)
(forward 5=-TGCACTGAGTGTGGAAAAGC-3=; reverse
5=-TGGTGATGCTGAAAGAGACG-3=); ZEB2 (forward 5=-
AGGCATATGGTGACGCACAA-3=; reverse 5=-CTTGA
ACTTGCGGTTACCTGC-3=).
SYBR Green was Used as the Detector and
ROX as the Passive Reference Gene
Results (means  SD) represent three animals as de-
scribed in the legend. The data were analyzed using the
Comparative CT method (
CT method). Differences in
CT are used to quantify relative amount of PCR target
contained within each well. The data were expressed as
relative mRNA expression in reference to control, normal-
ized to quantity of RNA input by performing measure-
ments on an endogenous reference gene, GAPDH.
Ang II ELISA
Ang II levels were determined in the renal tissue and
plasma samples from the protocol C using commercial
ELISA kits (Peninsula Laboratories, Belmont, CA) as
described by the manufacturer. Briefly, Ang II was
extracted with 20 mmol/L Tris buffer (pH 7.4) and par-
tially purified and concentrated after filtering through
tative microphotographs from Vpr with two, three, and four copies of Agtepresen
d microcyst formation. Segmental glomerular lesions are indicated by black
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Millipore, Billerica, MA).
Statistical Analysis
For comparison of mean values between two groups,
the unpaired t-test was used. To compare values be-
tween multiple groups, analysis of variance and a Bon-
ferroni multiple range test was used to calculate a P
value. Statistical significance was defined as P  0.05.
Results
There was no difference in clinical biomarkers (protein-
uria and blood pressure) between control Vpr (C-Vpr)
and Vpr-Agt-2-receiving doxycycline for 3 weeks
only.
Doxycycline-Treated Vpr Mice Displayed
Apparent HIVAN
Renal cortical sections from protocol A were evaluated to
confirm the development of apparent HIVAN phenotype
Figure 5. Severity of renal lesions correlated with number of Agt copies
(protocol B). A: Renal cortical sections were scored for the severity of
glomerular lesions. Vpr-Agt-4 showed advanced sclerotic glomerular lesions
when compared with Vpr-Agt-2. *P  0.01 compare with respective focal
segmental glomerulosclerosis (FSGS) of Vpr-Agt-2; **P 0.05 compared with
respective global glomerulosclerosis (GGS) of Vpr-Agt-2 and Vpr-Agt-3;
***P 0.05 compared with respective collapsing glomerulosclerosis (CGS) of
Vpr-Agt-2. B: Renal cortical sections were scored for the severity of tubular
lesions. Vpr-Agt-4 showed advanced tubular lesions when compared with
Vpr-Agt-2. *P  0.05 compared with respective Vpr-Agt-2; **P  0.05 com-
pared with respective Vpt-Agt-2; ***P  0.01 compared with respective
† ‡Vpr-Agt-2; P  0.05 with respective Vpr-Agt-2; P  0.05 with respective
Vpr-Agt-3; §P  0.001 compared with respective Vpr-Agt-2.in Vpr mice. Doxy-Vpr showed mean elevated levels of
urinary protein/creatinine ratio (Doxy-Vpr, 780 and C-Vpr,
210 mg/g creatinine) and blood pressure (Doxy-Vpr,
131.2/91.5 vs. C-Vpr, 126.8/87.2 mm Hg) when com-
pared with control mice (C-Vpr). Doxy-Vpr also showed
development of HIVAN phenotype in the form of focal
segmental glomerulosclerosis and microcyst formation
(Figure 2).
Figure 6. Vpr-Agt-4 displayed progressive renal lesions despite being off
doxycycline (protocol C). A: Renal cortical sections of Vpr-Agt-4, Vpr-Agt-3,
and Vpr-Agt-2 were scored for the severity of glomerular lesions. Vpr-Agt-4
showed advanced glomerular lesions when compared with Vpr-Agt-2 and
Vpr-Agt-3. *P  0.01 compared with respective focal segmental glomerulo-
sclerosis (FSGS) of Vpr-Agt-2 and Vpr-Agt-3; **P  0.01 compared with
respective global glomerulosclerosis (GGS) of Vpr-Agt-2 and Vpr-Agt-3;
***P 0.05 compared with respective collapsing glomerulosclerosis (CGS) of
Vpr-Agt-2. B: Renal cortical sections of Vpr-Agt-4, Vpr-Agt-3, and Vpr-Agt-2
were scored for the severity of tubular lesions. Vpr-Agt-4 showed advanced
tubular lesions when compared with Vpr-Agt-2. *P  0.05 compared with
Table 1. Mean Blood Pressure and UP/CR in Vpr Mice with
Variable Agt Copies (Protocol B)
Blood pressure
UP/CR
(mg/g
creatinine)
(mm Hg)
Systolic Diastolic
Vpr-Agt-2 130.1  2.1 89.2  1.5 850  150
Vpr-Agt-3 135.3  3.2* 93.8  2.2† 980  230
Vpt-Agt-4 140.2  4.3‡ 98.5  3.1§ 1090  350
*P  0.05 compared with respective Vpr-Ag2.
†P  0.05 compared with respective Vpr-Agt-2 and Vpr-Agt-2.
‡P  0.001 compared with respective Vpr-Agt-2 and Vpr-Agt-3.
§P  0.001 compared with respective Vpr-Agt-2.
UP/CR, urinary protein/creatinine.Vpr-Agt-2, 2; **P  0.05 compared with Vpt-Agt-2, 3; ***P  0.05 com-
pared with Vpr-Agt-2, microcyst.
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Expression of EMT Markers
EMT has been demonstrated to play an important role in
the progression of both human and animal experimental
models of kidney diseases.21 Since Ang II contributes to
the initiation of EMT, we also evaluated renal tissue ex-
pression of angiotensinogen (Agt) in Doxy-Vpr and C-
Vpr. To determine the role of EMT in the development of
HIVAN, total RNA was extracted from renal tissues of
Doxy-Vpr and C-Vpr (n 3). Doxy-Vpr showed enhanced
renal tissue mRNA expression of PCNA, -SMA, and
FSP1 when compared with C-Vpr (Figure 3). In addition,
renal tissues of Doxy-Vpr showed enhanced mRNA ex-
pression of SNAIL, ZEB1, and ZEB2 (repressors of tran-
scriptors of E-cadherin, Figure 3).21 Since renal tissue is
composed of multiple cell types, including mesenchymal
cells, an increase in PCNA and -SMA may be reflecting
events occurring in mesenchymal cells rather than in
epithelial cells; nonetheless, increased renal tissue ex-
pression of transcription repressors of E-cadherin (eg,
SNAIL, ZEB1, and ZEB2) indicated down-regulation of
epithelial cell phenotype. These findings indicate that
manifestation of the HIVAN phenotype is associated with
the expression of molecular markers of EMT.
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Table 2. Blood Pressure and UP/CR in Vpr-Agt-2 and Vpr-Agt-4
Mice (Protocol C)
Blood pressure
UP/CR ratio
(mg/g creatinine)
(mm Hg)
Systolic Diastolic
Vpr-Agt-2 125.2  3.8 81.5 2.9 150  80
Vpr-Agt-4 138.3  4.1* 96.8 3.1* 780  120*
*P  0.001 compared with respective Vpr-Agt-2.
UP/CR, urinary protein/creatinine.Renin ACE AngiotensinogActivation of the RAS Is Associated with the
Advanced Renal Lesions
To determine the role of the RAS in the progression of
renal lesions in HIVAN, we genetically engineered Vpr
mice with two, three, and four copies of Agt. These
mice were fed doxycycline for 6 weeks to display the
development of the HIVAN phenotype. Representative
microphotographs (protocol B) of Vpr-Agt-2, Vpr-
Agt-3, and Vpr-Agt-4 are shown in Figure 4. Vpr-Agt-4
showed advanced glomerular lesions when compared
with Vpr-Agt-2 (Figure 5A). Similarly, Vpr-Agt-4 mice
showed enhanced number of dilated tubules when
compared with Vpr-Agt-2 (Figure 5B). In addition, Vpr-
Agt-4 showed elevated levels of blood pressure and
increased amount of proteinuria when compared with
Vpr-Agt-2 (Table 1).
Vpr-Agt-4 Display Worsening of
Proteinuria, Blood Pressure, and Renal
Lesions (Protocol C)
In protocol C, Vpr mice with clinically occult HIVAN (with
only 3 weeks of doxycycline therapy) were exposed to
the graded degree of the RAS activation (by having two,
three, and four copies of Agt). Vpr-Agt-4 showed en-
hanced glomerular (Figure 6A) and tubular lesions (Fig-
ure 6B) when compared with Vpr-Agt-2 (protocol C). Vpr-
Agt-2 mice did not show any microcyst formation (Figure
6B); whereas both Vpr-Agt-3 and Vpr-Agt-4 showed mi-
crocyst formation (Figure 6B). Vpr-Agt-4 also showed
increased mean levels of blood pressure and urinary
protein/creatinine ratio when compared with Vpr-Agt-2
(Table 2).
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Figure 7. Vpr-Agt-4 showed the activation of the RAS. A:
Renal cortical sections of Vpr-Agt-2 and Vpr-Agt-4 mice were
immunolabeled for renin and angiotensinogen. Representa-
tive microphotographs from a Vpr-Agt-2 and a Vpr-Agt-4
mouse are shown. Both glomerular and tubular cells from
Vpr-Agt-4 mice displayed greater expression of renin as well
as angiotensinogen (indicated by brown staining). Tubular
cell expression of renin and angiotensinogen is indicated by
black and white arrows, respectively. Glomerular cell ex-
pression of angiotensinogen is indicated by a white arrow-
head.B:Total RNAwas extracted from renal cortical tissues of
Vpr-Agt-2 and Vpr-Agt-4 mice from the protocol C, and real-
time PCR studies were carried tomeasure Agt, renin, and ACE
expression. *P  0.001 compared with the respective Vpr--Agt-2
-Agt-4
**en
Agt-2; **P  0.01 compared with respective Vpr-Agt-2.
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Expression of Agt, Renin, and Angiotensin-
Converting Enzyme
To determine whether Vpr mice with higher Agt copies
had activation of the RAS, total RNA was extracted from
renal cortical tissues of Vpr-Agt-2 and Vpr-Agt-4 mice
from protocol C, and real-time PCR studies were per-
formed to measure Agt, renin, and ACE expression. As
shown in Figure 7, renal tissues of Vpr-Agt-4 mice
showed a three- to fourfold increase in renin and ACE
mRNA expression when compared to renal tissue ex-
pression of renin and ACE of Vpr-Agt-2. Similarly, Vpr-
Agt-4 showed twofold increase in renal tissue Agt expres-
sion. These findings indicate that Vpr-Agt-4 had activation
of the RAS.
Vpr-Agt-4 Show Higher Renal Tissue
Concentration of Ang II
To determine renal tissue and plasma concentration of
Ang II in Vpr-Agt-2 and Vpr-Agt-4, tissue lysates and
plasma were partially purified for Ang II (from renal cor-
tical tissue of Vpr-Agt-2 and Vpr Agt-4 from protocol C).
Ang II contents were measured by an ELISA kit as per
manufacturer’s protocol. As shown in Figure 8A, Vpr-
Agt-4 showed an 80% increase in renal tissue concen-
tration of Ang II when compared with renal tissue con-
centration of Vpr-Agt-2 (P 0.04). However, there was no
difference in plasma concentration of Ang II between
Vpr-Agt-2 and Vpr-Agt-4 (Figure 8B).
Figure 8. Vpr-Agt-4 showed elevated renal tissue concentration of Ang II. A:
Renal tissue lysates from Vpr-Agt-2 and Vpr-Agt-2 (protocol C, n  5) were
concentrated and Ang II assay was carried out by ELISA. Renal tissues of
Vpr-Agt-4 showed higher renal tissue concentration of Ang II. B: Plasma
samples of Vpr-Agt-4 and Vpr-Agt-2 were concentrated and Ang II concen-
tration was measured by ELISA.Renal Cell Expression of TGF- and CTGF in
Vpr-Agt-4
Renal cortical sections of Vpr-Agt-2 and Vpr-Agt-4 from
protocol C, were immunolabeled for TGF- and CTGF.
Representative microphotographs of renal cortical sec-
tions of a Vpr-Agt-2 (Figure 9A) and a Vpr-Agt-4 (Figure
Figure 9. Renal cell expression of CTGF in Vpr-Agt-4 and Vpr-Agt-2 (pro-
tocol C). A and B: Renal cortical sections of Vpr-Agt-2 (A) and Vpr-Agt-4 (B)
were immunolabeled for CTGF. Tubular cells displayed enhanced expres-
sion of CTGF (indicated by arrows) in Vpr-Agt-4. C: Protein was extracted
from renal tissues of Vpr-Agt-2 (n  3) and Vpr-Agt-4 (n  3); Western blots
were prepared and probed for CTGF and actin. Cumulative data in the form
of bar diagrams and representative gels are shown. *P  0.05.9B) showing renal cell expression of CTGF are shown in
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enhanced expression of CTGF. Representative immuno-
blots of renal tissue expression of CTGF in Vpr-Agt-2 and
Vpr-Agt-4 are shown in Figure 9C. Renal tissue in Vpr-
Agt-4 mice showed enhanced (P  0.05) expression of
CTGF when compared to Vpr-Agt-2. These findings indi-
cate that enhanced renal cell production of CTGF in
Vpr-Agt-4.
Representative microphotographs showing renal cor-
tical expression of TGF- in Vpr-Agt-2 and Vpr-Agt-4 are
shown in Figure 10, A and B, respectively. Both glomer-
ular and tubular cells showed enhanced expression of
TGF- in Vpr-Agt-4 when compared to Vpr-Agt-2. Since
TGF- has been known to induce its profibrotic effects
through the generation of CTGF in other disease modelsof kidney diseases,22 we wondered whether CTGF and
TGF- expression was displayed by the same cells. To
determine a spatial relationship between renal cell CTGF
and TGF- expression, we immunolabeled serial renal
cortical sections of Vpr-Agt-4 for CTGF and TGF-. As
shown in Figure 10, C and D, not all cells displaying
expression of TGF- showed enhanced expression
of CTGF.
Renal Cell and Tissue Expression of VEGF
Since renal cell VEGF expression has been demon-
strated to contribute to HIVAN pathogenesis,23 renal cor-
tical sections from protocol C were immunolabeled for
VEGF. Representative microphotographs are shown in
Figure 10. Renal tubular cells show enhanced
expression of TGF- and spatial relationship
with CTGF in Vpr-Agt-4. Renal cortical sections
of Vpr mice from the protocol C were immuno-
labeled for TGF-. Representative microphoto-
graphs from Vpr-Agt-2 (A) and Vpr-Agt-4 (B) are
shown. Tubular cells of Vpr-Agt-4 showed en-
hanced expression of TGF- (indicated by
brown staining). C and D: Serial sections from
Vpr-Agt-4 were immunolabeled for CTGF and
TGF-. Representative micrographs showing re-
nal cell labeling for CTGF (C) and TGF- (D) are
shown. Only a limited number of cells displayed
labeling for both CTGF and TGF- (indicated by
arrows).
Figure 11. Vpr-Agt-4 display enhanced renal
cell/tissue VEGF expression. Renal cortical sec-
tions from protocol C were immunolabeled for
VEGF. A and B: Representative microphoto-
graphs from a Vpr-Agt-2 (A) and a Vpr-Agt-4
(B). Tubular cells in Vpr-Agt-4 displayed en-
hanced expression of VEGF. C: Representative
gels displaying renal tissue expression of VEGF
and actin from Vpr-Agt-2 and Vpr-Agt-4. D: A
bar diagram showing cumulative data of renal
tissue VEGF/actin ratio from four Vpr-Agt-2 and
four Vpr-Agt-4 mice. *P  0.01
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enhanced expression of VEGF. Representative gels from
renal tissues of Vpr-Agt-2 and Vpr-Agt-4 are shown in
Figure 11C; whereas cumulative data renal tissue VEGF
expression is shown in Figure 11D. Renal tissues of Vpr-
Agt-4 displayed enhanced expression of VEGF (P 
0.01) when compared with Vpr-Agt-2.
Vpr-Agt-4 Showed Enhanced Renal Tissue
Expression of EMT Markers
To determine whether EMT is contributing to the progres-
sion to apparent HIVAN in Vpr-Agt-4, total RNA was ex-
tracted from renal tissues of Vpr-Agt-4 and Vpr-Agt-2
(protocol C). Vpr-Agt-4 showed enhanced renal tissue
expression of -SMA (Figure 12A). Moreover, renal tis-
sues of Vpr-Agt-4 mice showed enhanced expression of
ZEB2 (Figure 12A), a repressor of the transcriptor of
E-cadherin.21 These findings indicated that manifestation
of clinically apparent HIVAN was associated with the
activation of the transcriptor factors, which promote the
loss of epithelial cell phenotype.
To confirm whether enhanced renal tissue transcription
of -SMA also results in increased -SMA protein pro-
duction, renal tissue Western blots from Vpr-Agt-2 and
Vpr-Agt-4 were probed for -SMA. Representative gels
and cumulative data displaying renal tissue expression of
-SMA are shown in Figure 12B. Renal tissues from Vpr-
Agt-4 displayed enhanced (P  0.01) expression of
-SMA.
To determine whether enhanced renal tissue transcrip-
tion in Vpr-Agt-4 also repress renal tissue expression of
E-cadherin in Vpr-Agt-4, Western blots from renal tissues
from Vpr-Agt-2 and Vpr-Agt-4 were probed for E-cad-
herin. Representative gels and cumulative data display-
ing renal tissue expression of E-cadherin are shown in
Figure 12C. Renal tissues from Vpr-Agt-4 displayed di-
minished (P  0.03) expression of E-cadherin.
Since VEGF is a growth promoting factor and -SMA is
a marker of proliferating myofibroblasts, we wondered
whether VEGF and -SMA expression was displayed by
the same cells. To determine a spatial relationship be-
tween VEGF and -SMA expression, we immunolabeled
serial renal cortical sections of Vpr-Agt-4 for VEGF and
-SMA. As shown in Figure 13, not all cells showing
expression of VEGF displayed expression of -SMA.
Discussion
The present study demonstrates that Vpr mice after 6
weeks of doxycycline treatment (protocol A) developed
apparent HIVAN. In protocol B, tubular dilation and the
number of sclerosed glomeruli correlated with the num-
ber of Agt copies. In protocol C, Vpr-Agt-2 mice devel-
oped minimal glomerular lesions and only mild tubular
dilation and no microcyst formation; whereas Vpr-Agt-4
mice showed glomerular sclerosis, mild-to-moderate tu-
bular dilation and microcyst formation. Vpr-Agt-4 mice
not only showed enhanced mRNA expression of Agt,
renin, and ACE, but also showed an 80% increase inrenal tissue levels of Ang II when compared to Vpr-Agt-2.
These findings indicate that mice with four Agt copies
had renal tissue RAS activation. Degree of proteinuria
and level of blood pressure in Vpr-Agt-2 (protocol C)
were comparable to the proteinuria and blood pressure
levels of the control Vpr animals (C-Vpr, protocol A); On
the other hand, Vpr-Agt-4 displayed an increased
amount of proteinuria and elevated levels of blood pres-
sure when compared with Vpr-Agt-2 (protocol C) and
C-Vpr (protocol A). These findings suggest that the RAS
activation in Vpr-Agt-4 (protocol C) was associated with
Figure 12. Enhanced renal tissue expression of EMT markers by Vpr-Agt-4. A:
Total RNA was extracted from renal tissues of Vpr-Agt-4 and Vpr-Agt-2 (protocol
C). RNA was probed for -SMA and ZEB2 by real-time PCR studies. Vpr-Agt-4
showed enhanced renal tissue expression of -SMA and ZEB2. *P  0.01
compared with respective Vpr-Agt-2. B: Protein was extracted from renal tissue
of Vpr-Agt-2 (n  3) and Vpr-Agt-4), Western blots were prepared and probed
for -SMA. Cumulative data are shown in the form of a bar diagram. Represen-
tative gels showing expression of -SMA and actin are also shown. *P 0.01. C:
Protein was extracted from renal tissue of Vpr-Agt-2 (n 3) and Vpr-Agt-4 (n
3), Western blots were prepared and probed for E-cadherin. Cumulative data are
shown in the form of a bar diagram. Representative gels showing expression of
E-cadherin and actin are also shown.the progression of occult HIVAN to apparent HIVAN.
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cific genetic, environmental, and host factors.17,19 Re-
cently, the MYH9 and Apol1 genes have been linked to
the development of focal glomerulosclerosis in
Blacks.24,25 It has been suggested that the same genes
may be contributing to the occurrence of focal glomeru-
losclerosis in patients with HIV-1 infection.19 In addition,
manifestation of HIVAN requires infection of kidney cells
and the presence of specific host factors.17 Activation of
the RAS has been considered to contribute to the patho-
genesis of chronic kidney diseases, including HIVAN.26–29
On that account, blockade of Ang II type I receptors or
inhibition of the production of Ang II, are commonly used
therapeutic modalities to slow down the progression of
HIVAN.28,29 Conversely, infusion of Ang II has been dem-
onstrated to accelerate the progression of HIVAN in Vpr
mice.30 However, in these studies, the status of the RAS
activation was not determined. In the present study, we
have used mice with higher Agt copies, which not only
manifested with high renal tissue Ang II levels, but also
developed increased renal tissue expression of renin and
ACE. Thus, the findings in the present study indicated
that occult HIVAN could progress to apparent HIVAN in
the presence of the RAS activation.
In the present study, there was no difference in plasma
concentrations of Ang II between Vpr-Agt-2 and Vpr-
Agt-4 mice. It has been reported in several models of Ang
II–mediated hypertension that serum Ang II levels are
elevated during the initiation of the disease; however,
Ang II levels normalized during the later time periods.
Nevertheless, Ang II–mediated injury continued to be
displayed in these models.31 Our findings in the present
study are consistent with the findings of these investiga-
tors.
During the last decade, the role of tissue production of
Ang II has been demonstrated to contribute to tissue
injury.32 Since kidney cells, including podocytes, mesan-
gial and tubular cells carry machinery to generate Ang II,
the local production of Ang II has been demonstrated to
correlate with renal tissue injury in several models of
kidney injury.33,34 In the present study, renal tissue of
Vpr-Agt-4 displayed enhanced expression of renin, ang-
iotensinogen, and ACE. In addition, renal tissues of Vpr-
Agt-4 mice showed an 80% increase in Ang II production
when compared to Ang II production by renal tissues of
Vpr-Agt-2 mice.In several models of kidney diseases, including
HIVAN, the RAS activation has been demonstrated to
mediate many of its profibrotic effect by stimulating renal
cell TGF- production.35 TGF- has been reported to
stimulate renal fibrosis by stimulating renal cell CTGF in a
diabetic rat model of glomerulosclerosis.36 In the present
study, renal cells showed enhanced expression, not only
of TGF-, but also of CTGF. In the present study, all renal
cells expressing TGF- did not display CTGF expression.
It is possible that TGF- may have both autocrine and
paracrine effects.
Increased VEGF expression by kidney cells has
been reported to contribute to the proliferative pheno-
type in a mouse model of HIVAN.23 On the other hand,
inhibition of renal cell VEGF receptor 1 (VEGFR1) and
VEGFR2 was associated with a reduction in cyst size in
a mouse model of polycystic kidney disease.37 In the
present study, kidney cells showed enhanced expres-
sion of VEGF Vpr-Agt-4 when compared to Vpr-Agt-2.
Several renal cells not only showed expression of
VEGF, but also displayed expression of -SMA. It ap-
pears that VEGF may also be contributing to the pro-
liferation of cells undergoing EMT.
In C57B6 mice, blood pressures of one-copy
(Agttm1Unc/) through four-copy (Agtdup/Agtdup) animals
showed a linear increases of approximately 8 mm Hg per
gene copy20; however, in the present study, Vpr mice
displayed an increment of 5 mm Hg per Agt copy. This
discrepancy in the rate of increase in blood pressure per
gene copy may be related to their altered genetic back-
ground- from C57B6 to FVB/N. However, the modulating
effect of proteinuric disease on the blood pressure also
needs to be taken into account.
Since Vpr-Agt-4 mice showed higher levels of blood
pressure when compared with Vpr-Agt-2 mice, it is
possible that higher levels of Ang II may have contrib-
uted directly as well as indirectly though the develop-
ment of hypertension in the progression of renal lesions
in Vpr-Agt-4 mice. However, hypertension-mediated in-
jury has not been reported to display microcyst forma-
tion in any other human and animal experimental ani-
mal models. Therefore, the presence of microcyst
formation in Vpr-Agt-3 and Vpr-Agt-4 mice seems to be
the manifestation of HIV-1 gene (Vpr) expression in the
presence of specific host factors, such as the activa-
Figure 13. Spatial relationship between renal
cell expression of VEGF and -SMA in Vpr-
Agt-4. A and B: Serial sections from Vpr-Agt-4
were immunolabeled for VEGF and -SMA (pro-
tocol C). Representative micrographs showing
renal cell labeling for VEGF (A) and -SMA (B)
are shown. Only a limited number of cells dis-
played labeling for both VEGF and TGF- (in-
dicated by arrows).tion of the RAS.
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gression of fibrosis in kidney disease has been increas-
ingly recognized, it is still being debated.38 An inflamma-
tory milieu has been reported to invoke EMT in adult
tubular epithelial cells in the majority of the studies.38,39
Occurrence of mesenchymal phenotype was identified
by cellular expression of SMA and FSP1.38–40 Since
both -SMA and FSP1 lack cell specificity and constancy
of expression, they are not considered to be unequivocal
markers of specific lineage; moreover, FSP1 expression
in several tissues, including injured kidneys, was de-
tected in macrophages and not in myofibroblasts.39–41
Several transcription factors (Snail, Twist, Slug, and Id),
which regulate migration, activation, and differentiation
(functional characteristics of mesenchymal cells), are
also displayed by injured epithelial cells, myofibro-
blasts, and macrophages.40,42 Although the data in in
vitro studies are robust, in vivo studies lack absolute
proof of transition from epithelial to mesenchymal phe-
notype.38 In the present study, Vpr Agt-4 mice dis-
played enhanced renal tissue expression of so-called
EMT markers. It is likely that Ang II might have contrib-
uted indirectly to the progression of renal lesions
through the induction of EMT. However, both podo-
cytes and tubular cells transduced with HIV-1 have
been reported to show expression of EMT markers.21
Thus, it is possible that both the activation of the RAS
and HIV-1 expression might have contributed to the
expression of EMT markers in Vpr mice with four Agt
copies. Since, we have not determined the lineage of
cells displaying mesenchymal phenotype, it will be
difficult to identify their source of origin. Thus, it will be
important to investigate this aspect in future studies.
What is the relevance of the present occult HIVAN
model in real-life situations? A large number of HIV pa-
tients belong to African American background.1 There is
a variable lag period between the development of infec-
tion and its diagnosis. We speculate that during that lag
period, if kidney cells such as podocytes were infected
with HIV-1 and developed HIV-1 protein expression; they
are likely to display HIVAN phenotype in the presence of
adverse host factors during the later time periods. Since
podocytes are terminally differentiated cells, HIV-1 ex-
pression in these cells (occult HIVAN) may persist de-
spite eradication of viral infection. Moreover, the present
study demonstrated that expression of a single HIV-1
protein—Vpr—was capable of promoting HIVAN pheno-
type in the presence of adverse host factor: the activation
of the RAS.
The present study indicates that patients with occult
HIVAN carry a risk of developing apparent HIVAN in a
scenario of the activation of the RAS in the latter time
period as a consequence of loss of critical nephron mass
in commonly encountered conditions such as ingestion of
nephrotoxic medications, hypertension, diabetes, and
obesity.15,26
We conclude that host factors such as the activation of
the RAS have a potential to promote the progression of
clinically occult HIVAN into apparent HIVAN.Acknowledgments
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